Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vesicular Stomatitis Virus-Based Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirus

19 Dec 2013

Abstract excerpt

Ebola virus (EBOV) causes severe and often fatal hemorrhagic fever in humans and nonhuman primates (NHPs). Currently, there are no licensed vaccines or therapeutics for human use. Recombinant vesicular stomatitis virus (rVSV)-based vaccine vectors, which encode an EBOV glycoprotein in place of the VSV glycoprotein, have shown 100% efficacy against homologous Sudan ebolavirus (SEBOV) or Zaire ebolavirus (ZEBOV)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis B Virus Studies
Share to Viral Infections and Outbreaks Research
Share to Viral Infections and Vectors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24367715
DOI: 10.1371/journal.pntd.0002600

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vesicular Stomatitis Virus-Based Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirusPMID 24367715Read ↗

Single Immunization With a Monovalent Vesicular Stomatitis Virus–Based Vaccine Protects Nonhuman Primates Against Heterologous Challenge With Bundibugyo ebolavirusSemantic proximity Read ↗

Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman PrimatesSemantic proximity Read ↗

Homologous and Heterologous Protection of Nonhuman Primates by Ebola and Sudan Virus-Like ParticlesSemantic proximity Read ↗

Demonstration of Cross-Protective Vaccine Immunity against an Emerging Pathogenic Ebolavirus SpeciesSemantic proximity Read ↗

Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trialsSemantic proximity Read ↗

rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessmentSemantic proximity Read ↗

A single dose intranasal combination panebolavirus vaccineSemantic proximity Read ↗

A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challengeSemantic proximity Read ↗

Induction of Broad Cytotoxic T Cells by Protective DNA Vaccination Against Marburg and EbolaSemantic proximity Read ↗

Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and SenegalSemantic proximity Read ↗

The rVSV-EBOV vaccine provides limited cross-protection against Sudan virus in guinea pigsSemantic proximity Read ↗

A Single-Vector, Single-Injection Trivalent Filovirus Vaccine: Proof of Concept Study in Outbred Guinea PigsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.